Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants
Cancer Medicine · 2024
DOI: 10.1002/cam4.7430 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Tasuku Nakabori und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antibodies, Monoclonal, Humanized, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
Atezolizumab and bevacizumab (Atezo/Bev) combination immunotherapy regimens and direct oral anticoagulants (DOACs) are both associated with bleeding. Therefore, combining Atezo/Bev regimens with DOACs may exacerbate the bleeding risk. This study investigated the feasibility of the Atezo/Bev regimen in patients taking DOACs.
Methods
This retrospective study included 141 patients with unresectable hepatocellular carcinoma (HCC) or advanced lung cancer (LC) treated with Atezo/Bev regimens. Patients who used antithrombotic agents other than DOACs were excluded. Bleeding events during the Atezo/Bev regimen were analyzed.
Results
The incidence rates of bleeding of any grade in the DOAC ( n = 11) and no antithrombotic agent (NAA) ( n = 130) groups were 9.1% and 10.8%, respectively, with no significant differences. Moreover, no significant difference was found in the frequency of bleeding of grade ≥3 between the DOAC and NAA groups. No patients in the DOAC group discontinued the Atezo/Bev regimen because of severe bleeding. Although serum albumin levels, with a hazard ratio (HR) of 0.298 (95% confidence interval [CI]: 0.105–0.847), independently contributed to bleeding events ( p = 0.023), DOAC administration did not (HR: 1.357; 95% CI: 0.157–10.54; p = 0.770). Among only patients with HCC ( n = 59), none of the five patients taking DOACs experienced bleeding events. A high albumin–bilirubin score (HR: 9.083, 95% CI: 1.118–73.76) was associated with bleeding events ( p = 0.039).
Conclusions
DOACs did not have a considerable effect on bleeding events in the Atezo/Bev regimens for HCC or LC. Under careful surveillance for bleeding, Atezo/Bev regimens may be feasible in patients receiving DOACs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
ORCID-Profile: Tasuku Nakabori
Zitieren
APA
Nakabori, T., Kunimasa, K., Kawabata, M., Higashi, S., Mukai, K., Kawamura, T., Inoue, T., Tamiya, M., Nishino, K., & Ohkawa, K. (2024). Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants. Cancer Medicine. https://doi.org/10.1002/cam4.7430
Vancouver
Nakabori T, Kunimasa K, Kawabata M, Higashi S, Mukai K, Kawamura T, et al. Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants. Cancer Medicine. 2024. doi:10.1002/cam4.7430
BibTeX
@article{Nakabori2024,
author = {Nakabori, Tasuku and Kunimasa, Kei and Kawabata, Masaki and Higashi, Sena and Mukai, Kaori and Kawamura, Takahisa and Inoue, Takako and Tamiya, Motohiro and Nishino, Kazumi and Ohkawa, Kazuyoshi},
title = {Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7430}
}
EUVIMED